Optimizing Treatment for HR+/HER2- Metastatic Breast Cancer

Expert panelists review data presented at recent conferences and discuss current strategies utilized in the management of HR+ metastatic breast cancer.

EP. 1: Patient Scenario 1: A Case of Stage II HR+ Breast Cancer

December 16th 2022

Centering discussion on a patient scenario of stage II HR+ breast cancer, expert panelists consider how they would approach workup and selection of therapy.

EP. 2: Role of CDK4/6 Inhibitors as First-Line Therapy for Metastatic HR+ Breast Cancer

January 10th 2023

Comprehensive insight to the selection of CDK4/6 inhibitors as first-line therapy for patients with metastatic HR+ breast cancer, followed by a brief review of available endocrine partners.

EP. 3: HR+ Breast Cancer: Factors in Selecting First-Line Therapy for Metastatic Disease

January 10th 2023

Highlights from key clinical data informing the selection of targeted therapy in particular subsets of patients with HR+ breast cancer.

EP. 4: Patient Scenario 2: A Case of Relapsed HR+ Metastatic Breast Cancer

January 17th 2023

Expert perspectives review a case of relapsed HR+ metastatic breast cancer and consider treatment options available in the second line and beyond.

EP. 5: Novel Treatment Modalities Under Investigation in HR+ Metastatic Breast Cancer

January 17th 2023

After briefly addressing resistance to endocrine therapy, expert panelists broadly review novel treatment modalities in the setting of HR+ metastatic breast cancer.

EP. 6: Considering HER2-Directed Therapy in HER2-Low Metastatic Breast Cancer

January 24th 2023

Centering discussion on HER2-targeted trastuzumab deruxtecan, experts reflect on the presence of HER2-low metastatic breast cancer and optimal treatment strategies.

EP. 7: Potential for Targeting Trop-2 in HR+ Metastatic Breast Cancer

January 24th 2023

A brief review of Trop-2 directed therapy and its role in the HR+ metastatic breast cancer treatment landscape.

EP. 8: Other Targets in HR+ Breast Cancer: PARP Inhibition and Immune Checkpoint Inhibitors

January 31st 2023

Expert panelists consider the appropriate use of PARP and immune checkpoint inhibitors, respectively, in the setting of HR+ metastatic breast cancer.

EP. 9: Evolving Landscape of HR+ Metastatic Breast Cancer Management

January 31st 2023

Closing out their review of treatment strategies for HR+ metastatic breast cancer, a panel of experts highlights ongoing investigations and future directions in care.